Review of NICE Technology Appraisal Guidance No.183; Topotecan for the treatment of recurrent and stage IVB cervical cancer

Proposal to move the guidance to the static list

The planned date for review of the above guidance is September 2012.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

There is no significant evidence that would lead to a change in the recommendations made in TA183.  Since the publication of TA183, the patent for topotecan has expired and cheaper formulations are now available.  Results from a recently published cost-effectiveness analysis suggest that the reduction in price for topotecan is unlikely to have an impact on the existing recommendation for women who have previously received cisplatin.  Consequently we propose that the original guidance become static.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see appendix A for a full list of the organisations we have contacted. 

September 2012